ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Please see full Prescribing Information, including Boxed WARNING.
Read the complete Phase III publication in NEJM.
Please note that portions of the journal article contain information not included in the approved Prescribing Information for ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Please see Important Safety Information and full Prescribing Information, including Boxed WARNING.
Celgene Corporation provided support for the clinical trial discussed in the article. Please review the disclosures in the publication.
Click "OK" to proceed or "CANCEL" to return to ABRAXANE.com.